{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:18:50Z","timestamp":1791256730469,"version":"4.1.0"},"reference-count":30,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.3892\/or.2014.3268","type":"journal-article","created":{"date-parts":[[2014,6,13]],"date-time":"2014-06-13T12:24:43Z","timestamp":1402662283000},"page":"553-558","source":"Crossref","is-referenced-by-count":37,"title":["The PI3K\/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma"],"prefix":"10.3892","volume":"32","author":[{"given":"TETSURO","family":"OISHI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HIROAKI","family":"ITAMOCHI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AKIKO","family":"KUDOH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MICHIKO","family":"NONAKA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MISAKI","family":"KATO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MAYUMI","family":"NISHIMURA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NAO","family":"OUMI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SEIYA","family":"SATO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JUN","family":"NANIWA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SHINYA","family":"SATO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MUNEAKI","family":"SHIMADA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JUNZO","family":"KIGAWA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TASUKU","family":"HARADA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2014,6,13]]},"reference":[{"key":"key20180107210052_b1-or-32-02-0553","first-page":"5","article-title":"World Health Organization classification and nomenclature of ovarian cancer","volume":"42","author":"Scully","year":"1975","journal-title":"J Natl Cancer Inst Monogr"},{"key":"key20180107210052_b2-or-32-02-0553","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1006\/gyno.2001.6536","article-title":"Survival among U.S. women with invasive epithelial ovarian cancer","volume":"84","author":"McGuire","year":"2002","journal-title":"Gynecol Oncol"},{"key":"key20180107210052_b3-or-32-02-0553","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/0090-8258(89)90637-9","article-title":"Ovarian clear cell adenocarcinoma","volume":"32","author":"Kennedy","year":"1989","journal-title":"Gynecol Oncol"},{"key":"key20180107210052_b4-or-32-02-0553","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5","article-title":"Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy","volume":"88","author":"Sugiyama","year":"2000","journal-title":"Cancer"},{"key":"key20180107210052_b5-or-32-02-0553","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","article-title":"The PI3K pathway as drug target in human cancer","volume":"28","author":"Courtney","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20180107210052_b6-or-32-02-0553","doi-asserted-by":"crossref","first-page":"779","DOI":"10.4161\/cbt.5.7.2751","article-title":"Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms","volume":"5","author":"Nakayama","year":"2006","journal-title":"Cancer Biol Ther"},{"key":"key20180107210052_b7-or-32-02-0553","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1158\/1078-0432.CCR-06-2660","article-title":"Integrative genomic analysis of phosphatidylinositol 3\u2032-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer","volume":"13","author":"Zhang","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key20180107210052_b8-or-32-02-0553","first-page":"7678","article-title":"Mutation of the PIK3CA gene in ovarian and breast cancer","volume":"64","author":"Campbell","year":"2004","journal-title":"Clin Cancer Res"},{"key":"key20180107210052_b9-or-32-02-0553","doi-asserted-by":"crossref","first-page":"5853","DOI":"10.1038\/sj.onc.1207721","article-title":"AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth","volume":"23","author":"Altomare","year":"2004","journal-title":"Oncogene"},{"key":"key20180107210052_b10-or-32-02-0553","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1158\/1078-0432.CCR-09-0365","article-title":"mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary","volume":"15","author":"Mabuchi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20180107210052_b11-or-32-02-0553","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2353\/ajpath.2009.081000","article-title":"Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma","volume":"174","author":"Kuo","year":"2009","journal-title":"Am J Pathol"},{"key":"key20180107210052_b12-or-32-02-0553","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","article-title":"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity","volume":"7","author":"Maira","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"key20180107210052_b13-or-32-02-0553","doi-asserted-by":"crossref","first-page":"22299","DOI":"10.1073\/pnas.0905152106","article-title":"Specific apoptosis induction by the dual PI3K\/mTOR inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells","volume":"106","author":"Brachmann","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"key20180107210052_b14-or-32-02-0553","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1158\/1078-0432.CCR-09-3022","article-title":"The efficacy of the novel dual PI3-kinase\/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma","volume":"16","author":"Cho","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key20180107210052_b15-or-32-02-0553","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s13577-012-0048-1","article-title":"Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2","volume":"25","author":"Itamochi","year":"2012","journal-title":"Hum Cell"},{"key":"key20180107210052_b16-or-32-02-0553","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s13577-013-0062-y","article-title":"Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene","volume":"26","author":"Itamochi","year":"2013","journal-title":"Hum Cell"},{"key":"key20180107210052_b17-or-32-02-0553","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.1158\/1078-0432.CCR-11-0190","article-title":"Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun","volume":"17","author":"Itamochi","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20180107210052_b18-or-32-02-0553","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1593\/neo.05514","article-title":"Activating mutations and\/or expression levels of tyrosine kinase receptors GRB7, RAS, and BRAF in testicular germ cell tumors","volume":"7","author":"McIntyre","year":"2005","journal-title":"Neoplasia"},{"key":"key20180107210052_b19-or-32-02-0553","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2407-5-29","article-title":"Mutations of PIK3CA in gastric adenocarcinoma","volume":"5","author":"Li","year":"2005","journal-title":"BMC Cancer"},{"key":"key20180107210052_b20-or-32-02-0553","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ygyno.2012.02.016","article-title":"Prognostic determinants in patients with uterine and ovarian clear carcinoma","volume":"125","author":"Rauh-Hein","year":"2012","journal-title":"Gynecol Oncol"},{"key":"key20180107210052_b21-or-32-02-0553","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ygyno.2005.12.038","article-title":"Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience","volume":"102","author":"Pectasides","year":"2006","journal-title":"Gynecol Oncol"},{"key":"key20180107210052_b22-or-32-02-0553","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1440-1827.2008.02320.x","article-title":"Therapeutic strategy targeting the mTOR-HIF-1\u03b1-VEGF pathway in ovarian clear cell adenocarcinoma","volume":"59","author":"Miyazawa","year":"2009","journal-title":"Pathol Int"},{"key":"key20180107210052_b23-or-32-02-0553","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s10147-012-0459-8","article-title":"Clinical trials and future potential of targeted therapy for ovarian cancer","volume":"17","author":"Itamochi","year":"2012","journal-title":"Int J Clin Oncol"},{"key":"key20180107210052_b24-or-32-02-0553","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ceb.2009.10.007","article-title":"mTOR and cancer: many loops in one pathway","volume":"22","author":"Efeyan","year":"2010","journal-title":"Curr Opin Cell Biol"},{"key":"key20180107210052_b25-or-32-02-0553","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1083\/jcb.200403069","article-title":"The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins","volume":"166","author":"Harrington","year":"2004","journal-title":"J Cell Biol"},{"key":"key20180107210052_b26-or-32-02-0553","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/jcb.10135","article-title":"Role of mTOR in the degradation of IRS-1: regulation of PP2A activity","volume":"85","author":"Hartley","year":"2002","journal-title":"J Cell Biochem"},{"key":"key20180107210052_b27-or-32-02-0553","doi-asserted-by":"crossref","first-page":"e37431","DOI":"10.1371\/journal.pone.0037431","article-title":"Genotype-dependent efficacy of a dual PI3K\/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas","volume":"7","author":"Shoji","year":"2012","journal-title":"PLoS One"},{"key":"key20180107210052_b28-or-32-02-0553","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1158\/1535-7163.MCT-11-0723","article-title":"Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications","volume":"11","author":"Montero","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"key20180107210052_b29-or-32-02-0553","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1158\/1078-0432.CCR-10-2289","article-title":"Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma","volume":"17","author":"Santiskulvong","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20180107210052_b30-or-32-02-0553","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.humpath.2012.03.011","article-title":"Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma","volume":"43","author":"Rahman","year":"2012","journal-title":"Hum Pathol"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2014.3268\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T21:01:03Z","timestamp":1515358863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2014.3268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,13]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,6,13]]},"published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.3892\/or.2014.3268"],"URL":"https:\/\/doi.org\/10.3892\/or.2014.3268","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,13]]}}}